- UHRA Home
- Browsing by Author
Browsing by Author "Lalatsa, Aikaterini"
Now showing items 1-14 of 14
-
5.08 Drug Delivery across the Blood-brain barrier
Lalatsa, Aikaterini (Elsevier, 2011) -
Active Targeting
Serrano Lopez, Dolores Remedios; Lalatsa, Lalatsa (Springer Nature, 2013) -
Amphiphilic poly(l-amino acids) : New materials for drug delivery
Lalatsa, Aikaterini; Schaetzlein, Andreas G.; Mazza, Mariarosa; Thi Bich Hang Le, [No Value]; Uchegbu, Ijeoma F. (2012-07-20)The formulation of drug compounds into medicines will increasingly rely on the use of specially tailored molecules, which fundamentally alter the drug's pharmacokinetics to enable its therapeutic activity. This is particularly ... -
Blood-Brain Barrier Delivery Session Podium Presentation : Carbohydrate Amphiphiles Enable Oral Peptide Delivery to the Central Nervous System
Lalatsa, Aikaterini; Schatzlein, A. G.; Uchegbu, I.F. (2009) -
Carbohydrate Amphiphiles Enable Peptide Delivery to the CNS
Lalatsa, Aikaterini; Schatzlein, A. G.; Uchegbu, I.F. (2008) -
Imaging cortical vasculature with stimulated Raman scattering and two-photon photothermal lensing microscopy
Moger, Julian; Garrett, Natalie. L.; Begley, David; Mihoreanu, Larisa; Lalatsa, Aikaterini; Lozano, Maria Victoria; Mazza, Mariarosa; Schatzlein, Andreas; Uchegbu, Ijeoma (2012-05)The ability to map microvascular morphology and hemodynamic parameters, such as blood volume, is desirable for many biomedical studies and will lead to a deeper understanding of the mechanisms of angiogenesis and vascular ... -
Nanostructures Overcoming the Blood-Brain Barrier : Physiological Considerations and Mechanistic Issues
Lalatsa, Aikaterini (Royal Society of Chemistry, 2012) -
Oral Delivery of Hydrophilic Drugs to the Brain
Centre for Research into Topical Drug Delivery and Toxicology; Nanopharmaceutics; Pharmaceutics; Department of Pharmacy; School of Life and Medical Sciences; Health & Human Sciences Research Institute; Lalatsa, Aikaterini (2010-09-10)A composition comprising a lipophilic derivative of a hydrophilic drug and an amphiphile compound for use in therapy wherein the composition is orally administered to the human or animal body. The invention includes ... -
Oral nanomedicines for the treatment of brain diseases
Lalatsa, Aikaterini; Uchegbu, I.F. (2011) -
Oral polymeric nanomedicines for peptide delivery to the brain : Polymer molecular weight effect
Lalatsa, Aikaterini; Garrett, N. L.; Mojer, J.; Schatzlein, A. G.; Uchegbu, I.F. (2011)Poster T3058 at the AAPS Annual Meeting and Exposition -
Peptide pills for brain diseases? : Reality and future perspectives
Serrano Lopez, Dolores Remedios; Lalatsa, Aikaterini (2013-04)The peptide therapeutic market is one of the fastest growth areas of the pharmaceutical industry. Although few orally administered peptides are marketed and many are in different phases of clinical development, there is ... -
Peptides, Proteins and Antibodies
Lalatsa, Lalatsa (Springer Nature, 2013)Peptide and protein therapeutics are increasingly able to address a growing range of clinical pathologies and their high specificity and potency combined with low toxicity of metabolic products and minimal potential for ... -
Polymeric Nanoparticles
Uchegbu, I.F.; Lalatsa, Lalatsa; Wong, Dennis (Springer Nature, 2013)Self-assembling polymers, which are either amphiphilic block copolymers with hydrophobic and hydrophilic blocks, hydrophilic polymer backbones substituted with hydrophobic units or polymers with a low aqueous solubility, ... -
A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine(5)-enkephalin, to the brain
Lalatsa, Aikaterini; Lee, Vivian; Malkinson, John P.; Zloh, Mire; Schätzlein, Andreas G; Uchegbu, Ijeoma F. (2012-06)The oral use of neuropeptides to treat brain disease is currently not possible because of a combination of poor oral absorption, short plasma half-lives and the blood-brain barrier. Here we demonstrate a strategy for ...